Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
30 results about "Selective Progesterone Receptor Modulators" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
As a contribution, so-called Selective Progesterone Receptor Modulators (SPRMs) have been developed. They have been described as agents with mixed antagonistic and agonistic effects on progesterone receptors in a tissue specific manner, while minimizing interactions with other steroidal receptors.
5-cycloalkenyl 5H-chromeno[3,4-f]quinoline derivatives as selective progesterone receptor modulator compounds
ActiveUS7071205B2Improve fertilityReduced fertilityBiocideOrganic chemistryPR - Progesterone receptorQuinoline
The present invention is directed to compounds, pharmaceutical compositions, and methods for modulating processes mediated by Progesterone Receptor. Also provided are methods of making such compounds and pharmaceutical compositions.
![5-cycloalkenyl 5H-chromeno[3,4-f]quinoline derivatives as selective progesterone receptor modulator compounds](https://images-eureka.patsnap.com/patent_img/79204447-f7c0-4b00-939d-645ee2a3bb41/US07071205-20060704-C00001.png "5-cycloalkenyl 5H-chromeno[3,4-f]quinoline derivatives as selective progesterone receptor modulator compounds")
![5-cycloalkenyl 5H-chromeno[3,4-f]quinoline derivatives as selective progesterone receptor modulator compounds](https://images-eureka.patsnap.com/patent_img/79204447-f7c0-4b00-939d-645ee2a3bb41/US07071205-20060704-C00002.png "5-cycloalkenyl 5H-chromeno[3,4-f]quinoline derivatives as selective progesterone receptor modulator compounds")
![5-cycloalkenyl 5H-chromeno[3,4-f]quinoline derivatives as selective progesterone receptor modulator compounds](https://images-eureka.patsnap.com/patent_img/79204447-f7c0-4b00-939d-645ee2a3bb41/US07071205-20060704-C00003.png "5-cycloalkenyl 5H-chromeno[3,4-f]quinoline derivatives as selective progesterone receptor modulator compounds")
Owner:LIGAND PHARMA INC
5-(1',1'-cycloalkyl/alkenyl)methylidene 1,2-dihydro-5H-chromeno[3,4-ƒ]quinolines as selective progesterone receptor modulator compounds
ActiveUS7084151B2Improve fertilityReduced fertilityBiocideOrganic chemistryPR - Progesterone receptorQuinoline
The present invention is directed to compounds, pharmaceutical compositions, and methods for modulating processes mediated by Progesterone Receptor. Also provided are methods of making such compounds and pharmaceutical compositions.
![5-(1',1'-cycloalkyl/alkenyl)methylidene 1,2-dihydro-<i>5H</i>-chromeno[3,4-ƒ]quinolines as selective progesterone receptor modulator compounds](https://images-eureka.patsnap.com/patent_img/c08410d8-05dc-45d9-92b5-f7dcb5b56077/US07084151-20060801-C00001.png "5-(1',1'-cycloalkyl/alkenyl)methylidene 1,2-dihydro-<i>5H</i>-chromeno[3,4-ƒ]quinolines as selective progesterone receptor modulator compounds")
![5-(1',1'-cycloalkyl/alkenyl)methylidene 1,2-dihydro-<i>5H</i>-chromeno[3,4-ƒ]quinolines as selective progesterone receptor modulator compounds](https://images-eureka.patsnap.com/patent_img/c08410d8-05dc-45d9-92b5-f7dcb5b56077/US07084151-20060801-C00002.png "5-(1',1'-cycloalkyl/alkenyl)methylidene 1,2-dihydro-<i>5H</i>-chromeno[3,4-ƒ]quinolines as selective progesterone receptor modulator compounds")
![5-(1',1'-cycloalkyl/alkenyl)methylidene 1,2-dihydro-<i>5H</i>-chromeno[3,4-ƒ]quinolines as selective progesterone receptor modulator compounds](https://images-eureka.patsnap.com/patent_img/c08410d8-05dc-45d9-92b5-f7dcb5b56077/US07084151-20060801-C00003.png "5-(1',1'-cycloalkyl/alkenyl)methylidene 1,2-dihydro-<i>5H</i>-chromeno[3,4-ƒ]quinolines as selective progesterone receptor modulator compounds")
Owner:LIGAND PHARMA INC
Steroids derivatives as selective progesterone receptor modulators
The present invention is directed to novel steroid derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by at least one progesterone or glucocorticoid receptor.
Owner:JANSSEN PHARMA NV
Selective androgen receptor modulators and methods of use thereof
InactiveUS7919647B2Reduce incidenceDecreasing regressionBiocideOrganic chemistrySelective androgen receptor modulatorSelective progesterone receptor modulator
Owner:UNIV OF TENNESSEE RES FOUND
Sequential SPRM/ progestin treatment
InactiveUS20050215536A1BiocideOrganic active ingredientsGynecologySelective progesterone receptor modulator
The methods provided herein comprise administering a selective progesterone receptor modulator (SPRM) during a first dosing period and at least one progestogen during a second dosing period. The dosing periods can run concomitantly or sequentially with or without a period where neither the SPRM nor the progestogen is administered.
Owner:ABBOTT ENDOCRINE INC
Compositions and methods for treating dysfunctional uterine bleeding
InactiveUS20090118253A1Treating and preventing anemiaPrevent anemiaOrganic active ingredientsSexual disorderSubject matterProgesterones
The subject matter of the instant invention is pertinent to the field of hormone therapy. More specifically, the subject matter of the instant invention concerns methods of treating dysfunctional uterine bleeding. The instant invention is also relevant to the treatment and / or prevention of anemia in patients with dysfunctional uterine bleeding. Compositions for practicing the methods, comprising progesterone antagonists are also disclosed. Embodiments of the instant invention also disclose methods for identifying new selective progesterone receptor modulators for practicing disclosed methods of treatment.
Owner:APTALIS PHARMA
Mutagenesis of plants for overproduction of selective estrogen receptor modulators
ActiveUS9758788B2Mutant preparationVector-based foreign material introductionPlant cellSelective Progesterone Receptor Modulators
Owner:NAPROGENIX
Solid dispersion of a selective modulator of the progesterone receptor
InactiveUS20160213684A1Powder deliveryOrganic active ingredientsMetabolitePR - Progesterone receptor
The subject of the present invention is a solid dispersion comprising an active ingredient selected from the group consisting of selective progesterone receptor modulators, metabolites thereof and mixtures thereof, and a pharmaceutically acceptable polymeric excipient. The invention also relates to a pharmaceutical composition comprising said solid dispersion and to the therapeutic uses thereof.
Owner:LAB HRA PHARMA SA
Ethylene derivative serving as selective estrogen receptor modulators (SERMs)
InactiveCN102532073ANervous disorderOrganic chemistryDiseaseSelective Progesterone Receptor Modulators
The invention provides an ethylene derivative represented by a formula I. Serving as selective estrogen receptor modulators (SERMs), the ethylene derivative can be used for preventing and / or treating diseases or disease symptoms influenced by selective estrogen receptor modulation. The formula I is shown in the specifications.
Owner:CENTAURUS BIOPHARMA
Co-micronisation product comprising a selective progesterone-receptor modulator
The subject of the present invention is a co-micronization product comprising: an active ingredient selected from the group consisting of selective progesterone receptor modulators, metabolites thereof and mixtures thereof, and an N-vinyl-2-pyrrolidone-based polymeric excipient. The invention also relates to a pharmaceutical composition comprising said co-micronization product and to the therapeutic uses thereof.
Owner:LAB HRA PHARMA SA
Selective progesterone receptor modulators (SPRM) and stabilized estrogen level in patient
ActiveUS20180369257A1Peptide/protein ingredientsSulfur/selenium/tellurium active ingredientsDiseasePhysiology
The present invention is related to Selective Progesterone Receptor Modulators (SPRM) as described and defined herein, and covers the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of sexual hormone dependent diseases and gynaecological diseases in particular Endometriosis or Uterine Fibroids (UF), as a sole agent or in combination with other active ingredients wherein circulating endogenous estradiol concentration of treated women is maintained to a level in a range of 40 pg / mL to 85 pg / mL.
Owner:BAYER PHARMA AG
Sequential sprm/ progestin treatment
InactiveUS20100004214A1BiocideOrganic active ingredientsGynecologySelective progesterone receptor modulator
Owner:CHWALISZ KRISTOF
Copper intrauterine device
InactiveUS20150320766A1Inhibits motilityInhibits viabilityBiocideOrganic active ingredientsSide effectGynecology
The invention relates to a copper contraceptive intrauterine system (IUS) with a flexible frame, which system is further capable of releasing a selective progesterone receptor modulator (SPRM), such as ulipristal acetate, for reducing or preventing bleeding side effects.
Owner:LAB HRA PHARMA SA
Compositions and methods for suppressing endometrial proliferation
InactiveCN104997789AOrganic active ingredientsAntipyreticProgesteronesSelective progesterone receptor modulator
Owner:APTALIS PHARMA
5-Cycloalkenyl 5H-chromeno[3,4-f]quinoline derivatives as selective progesterone receptor modulator compounds
The present invention relates to methods for modulating processes mediated by progesterone receptor using nonsteroidal compounds and compositions which may be high affinity, high specificity agonists, partial agonists (i.e., partial activators and / or tissue-specific activators) and / or antagonists for progesterone receptors.
![5-Cycloalkenyl 5H-chromeno[3,4-f]quinoline derivatives as selective progesterone receptor modulator compounds](https://images-eureka.patsnap.com/patent_img/3f230340-4b76-41e4-abdd-2a85e0f53309/US20060194827A1-20060831-C00001.png "5-Cycloalkenyl 5H-chromeno[3,4-f]quinoline derivatives as selective progesterone receptor modulator compounds")
![5-Cycloalkenyl 5H-chromeno[3,4-f]quinoline derivatives as selective progesterone receptor modulator compounds](https://images-eureka.patsnap.com/patent_img/3f230340-4b76-41e4-abdd-2a85e0f53309/US20060194827A1-20060831-C00002.png "5-Cycloalkenyl 5H-chromeno[3,4-f]quinoline derivatives as selective progesterone receptor modulator compounds")
![5-Cycloalkenyl 5H-chromeno[3,4-f]quinoline derivatives as selective progesterone receptor modulator compounds](https://images-eureka.patsnap.com/patent_img/3f230340-4b76-41e4-abdd-2a85e0f53309/US20060194827A1-20060831-C00003.png "5-Cycloalkenyl 5H-chromeno[3,4-f]quinoline derivatives as selective progesterone receptor modulator compounds")
Owner:LIGAND PHARMA INC
Copper intrauterine device
InactiveUS20190008763A1Inhibits motilityInhibits viabilityOrganic active ingredientsInorganic active ingredientsSide effectGynecology
Owner:LAB HRA PHARMA SA
Oxa-steroids derivatives as selective progesterone receptor modulators
Owner:JANSSEN PHARMA NV
Sequential SPRM/progestin treatment
InactiveUS20050215535A1BiocideOrganic active ingredientsGynecologySelective progesterone receptor modulator
The methods provided herein comprise administering a selective progesterone receptor modulator (SPRM) during a first dosing period and at least one progestogen during a second dosing period. The dosing periods can run concomitantly or sequentially with or without a period where neither the SPRM nor the progestogen is administered.
Owner:ABBOTT ENDOCRINE INC
Compositions and methods for suppressing endometrial proliferation
ActiveUS20100216756A1Prevent proliferationWeak affinityOrganic active ingredientsNervous disorderSelective progesterone receptor modulatorEndometrial cancer
The subject matter of the instant invention is pertinent to the field of hormone therapy. More specifically, the subject matter of the instant invention concerns methods of treating estrogen-dependent conditions such as endometrial hyperplasia and endometrial cancer in a female undergoing estrogen and / or selective estrogen receptor modulator (SERM) therapy. The instant invention is also relevant to the suppression of endometrial proliferation. The instant invention is also relevant to the treatment of pain associated with endometriosis. The compositions for practicing the methods, comprising progesterone antagonists are also disclosed. Embodiments of the instant invention also disclose methods for identifying new selective progesterone receptor modulators for practicing disclosed methods of treatment.
Owner:APTALIS PHARMA
Oxa-steroids derivatives as selective progesterone receptor modulators
The present invention is directed to novel 7-oxa-estra-4,9-diene-3,17-dione derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by at least one progesterone or glucocorticoid receptor.
Owner:JANSSEN PHARMA NV
5-substituted 7,9-difluoro-5H-chromeno[3,4-f]quinoline compounds as selective progesterone receptor modulator compounds
InactiveUS7163946B2Improve fertilityReduced fertilityBiocideOrganic chemistryPR - Progesterone receptorQuinoline
The present invention is directed to compounds, pharmaceutical compositions, and methods for modulating processes mediated by progesterone receptor. Also provided are methods of making such compounds and pharmaceutical compositions.
![5-substituted 7,9-difluoro-5H-chromeno[3,4-f]quinoline compounds as selective progesterone receptor modulator compounds](https://images-eureka.patsnap.com/patent_img/3ffa70df-13a6-462b-b19c-4c6e0afc2346/US07163946-20070116-C00001.png "5-substituted 7,9-difluoro-5H-chromeno[3,4-f]quinoline compounds as selective progesterone receptor modulator compounds")
![5-substituted 7,9-difluoro-5H-chromeno[3,4-f]quinoline compounds as selective progesterone receptor modulator compounds](https://images-eureka.patsnap.com/patent_img/3ffa70df-13a6-462b-b19c-4c6e0afc2346/US07163946-20070116-C00002.png "5-substituted 7,9-difluoro-5H-chromeno[3,4-f]quinoline compounds as selective progesterone receptor modulator compounds")
![5-substituted 7,9-difluoro-5H-chromeno[3,4-f]quinoline compounds as selective progesterone receptor modulator compounds](https://images-eureka.patsnap.com/patent_img/3ffa70df-13a6-462b-b19c-4c6e0afc2346/US07163946-20070116-C00003.png "5-substituted 7,9-difluoro-5H-chromeno[3,4-f]quinoline compounds as selective progesterone receptor modulator compounds")
Owner:LIGAND PHARMA INC
Solid dispersions of selective progesterone receptor modulators
The subject of the present invention is a solid dispersion comprising an active ingredient selected from selective progesterone receptor modulators, their metabolites and mixtures thereof and a pharmaceutically acceptable polymeric excipient. The invention also relates to pharmaceutical compositions comprising said solid dispersions and their therapeutic use.
Owner:LAB HRA PHARMA SA
Progesterone Antagonists such as CDB-4124 in the Treatment of Breast Cancer
Owner:APTALIS PHARMA
Selective progesterone receptor modulator (SPRM) regimen
The invention is directed to a pharmaceutical composition comprising a progesterone receptor antagonist namely (11beta,17beta)-17-Hydroxy-11-[4-(methylsulphonyl)phenyl]-17-(pentafluoroethyl)estra-4,9-dien-3-one for the treatment and / or prophylaxis of Uterine Fibroids (myomas, uterine leiomyoma) that is administered to a patient diagnosed with Uterine Fibroids following a specific regimen. Additionally, the invention is directed to a method for treating Uterine Fibroids (myomas, uterine leiomyoma) and / or for reducing Uterine Fibroids (myomas, uterine leiomyoma) size and symptoms related to Uterine Fibroids following a specific regimen as well as treatment of Heavy Menstrual Bleeding (HMB).
Owner:BAYER PHARMA AG
Selective progesterone receptor modulator (SPRM) regimen
The invention is directed to a pharmaceutical composition comprising a progesterone receptor antagonist namely (11beta,17beta)-17-Hydroxy-11-[4-(methylsulphonyl)phenyl]-17-(pentafluoroethyl)estra-4,9-dien-3-one for the treatment and / or prophylaxis of Uterine Fibroids (myomas, uterine leiomyoma) that is administered to a patient diagnosed with Uterine Fibroids following a specific regimen. Additionally, the invention is directed to a method for treating Uterine Fibroids (myomas, uterine leiomyoma) and / or for reducing Uterine Fibroids (myomas, uterine leiomyoma) size and symptoms related to Uterine Fibroids following a specific regimen as well as treatment of Heavy Menstrual Bleeding (HMB).
Owner:BAYER PHARMA AG
5-(1',1'-cycloalkyl/alkenyl)methylidene 1,2-dihydro-5H-chromeno-[3,4-f]-quinolines as selective progesterone receptor modulator compounds
![5-(1',1'-cycloalkyl/alkenyl)methylidene 1,2-dihydro-5H-chromeno-[3,4-f]-quinolines as selective progesterone receptor modulator compounds](https://images-eureka.patsnap.com/patent_img/86b3c673-8343-4536-afa5-63d26a74da8f/US20060223839A1-20061005-C00001.png "5-(1',1'-cycloalkyl/alkenyl)methylidene 1,2-dihydro-5H-chromeno-[3,4-f]-quinolines as selective progesterone receptor modulator compounds")
![5-(1',1'-cycloalkyl/alkenyl)methylidene 1,2-dihydro-5H-chromeno-[3,4-f]-quinolines as selective progesterone receptor modulator compounds](https://images-eureka.patsnap.com/patent_img/86b3c673-8343-4536-afa5-63d26a74da8f/US20060223839A1-20061005-C00002.png "5-(1',1'-cycloalkyl/alkenyl)methylidene 1,2-dihydro-5H-chromeno-[3,4-f]-quinolines as selective progesterone receptor modulator compounds")
![5-(1',1'-cycloalkyl/alkenyl)methylidene 1,2-dihydro-5H-chromeno-[3,4-f]-quinolines as selective progesterone receptor modulator compounds](https://images-eureka.patsnap.com/patent_img/86b3c673-8343-4536-afa5-63d26a74da8f/US20060223839A1-20061005-C00003.png "5-(1',1'-cycloalkyl/alkenyl)methylidene 1,2-dihydro-5H-chromeno-[3,4-f]-quinolines as selective progesterone receptor modulator compounds")
Owner:LIGAND PHARMA INC
Selective progesterone receptor modulators (SPRM) and stabilized estrogen level in patient
ActiveUS10485808B2Peptide/protein ingredientsSulfur/selenium/tellurium active ingredientsDiseaseGynaecological disease
The present invention is related to Selective Progesterone Receptor Modulators (SPRM) as described and defined herein, and covers the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of sexual hormone dependent diseases and gynaecological diseases in particular Endometriosis or Uterine Fibroids (UF), as a sole agent or in combination with other active ingredients wherein circulating endogenous estradiol concentration of treated women is maintained to a level in a range of 40 pg / mL to 85 pg / mL.
Owner:BAYER PHARMA AG
Steroids derivatives as selective progesterone receptor modulators
Owner:JANSSEN PHARMA NV
Compositions and Methods for Suppressing Endometrial Proliferation
ActiveUS20140235602A1Weak affinityReduces luteal phase progesterone levelOrganic active ingredientsNervous disorderSelective progesterone receptor modulatorProgesterones
Owner:APTALIS PHARMA
Oral pharmaceutical compositions comprising an unmicronized selective progesterone receptor as active agent
InactiveUS20200069702A1Organic active ingredientsCapsule deliveryPR - Progesterone receptorActive agent
The subject matter of the present invention is pertinent to the field of oral delivery of pharmaceutically active agents. Embodiments of the instant invention disclose a liquid or semi-solid non-aqueous oral pharmaceutical fill composition comprising (a) a pharmaceutically effective amount of an unmicronized selective progesterone receptor modulator (SPRM) and (b) a polyethylene glycol (PEG) as well as methods for treating a variety of progesterone related disorders by orally administering such a composition.
Owner:APTALIS PHARMA
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com